GlassScriptPhysician profile
Joan M Dahmer
NPI 1417954785
$2,941.26
in general payments reported to CMS, 2019-2025
40 companies · $94.18 in 2025
The $94.18 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,935 · 2020: $17.24 · 2021: $185 · 2022: $191 · 2023: $140 · 2024: $379 · 2025: $94.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.19 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $259.68 | 2019-2022 | |
| Kyowa Kirin, INC. | $247.65 | 2021-2023 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $197.69 | 2019-2020 | |
| Inari Medical, INC. | $194.01 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $185.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $172.19 | 2019-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $150.32 | 2019-2024 | |
| Emd Serono, INC. | $124.56 | 2024 | |
| Janssen Biotech, INC. | $123.92 | 2019 | |
| Advanced Accelerator Applications | $120.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.60 | 2019 | |
| Celgene Corporation | $89.45 | 2019-2022 | |
| Amgen INC. | $89.00 | 2019 | |
| Daiichi Sankyo INC. | $76.92 | 2019 | |
| Genentech USA, INC. | $75.07 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $67.67 | 2019 | |
| Genzyme Corporation | $66.03 | 2019 | |
| Pfizer INC. | $61.02 | 2019-2022 | |
| Gilead Sciences, INC. | $55.38 | 2019-2023 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $46.00 | 2019 | |
| Progenics Pharmaceuticals, INC. | $39.75 | 2024-2025 | |
| Incyte Corporation | $34.18 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $33.00 | 2019 | |
| Astellas Pharma US INC | $32.76 | 2019 | |
| Spectrum Pharmaceuticals INC. | $27.91 | 2019 | |
| Covidien LP | $27.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.68 | 2019 | |
| Shire North American Group INC | $23.66 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $21.70 | 2019 | |
| Eisai INC. | $20.74 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.63 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.34 | 2019 | |
| Abbvie INC. | $17.56 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.54 | 2019 | |
| Apo-Pharma USA, INC. | $16.40 | 2019 | |
| Seagen INC. | $15.99 | 2019 | |
| Verastem, INC. | $13.41 | 2019 | |
| Tesaro, INC. | $12.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.04 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Dahmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.